<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685321</url>
  </required_header>
  <id_info>
    <org_study_id>0024-07-SHA</org_study_id>
    <nct_id>NCT00685321</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety and Efficacy of the H1-coil Deep Transcranial Magnetic Stimulation in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia</brief_title>
  <official_title>A Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:The purpose of the study is to explore the efficacy and safety of H1-Coil deep&#xD;
      brain rTMS in subjects with negative symptoms and cognitive deficits of schizophrenia&#xD;
      (deficit syndrome), currently treated with atypical antipsychotics.&#xD;
&#xD;
      Patient Population: The intention is to treat 45 patients diagnosed with schizophrenia, who&#xD;
      are currently suffering mainly from negative symptoms and cognitive deficits (deficit&#xD;
      syndrome). The patients will be of all racial, ethnic and gender categories, ranging from 18&#xD;
      to 65 years of age, and have PANSS negativeâ‰¥21 and PANSS positive&lt;24. Patients will be&#xD;
      recruited from both academic and private research centers.&#xD;
&#xD;
      Structure: The study is a randomized, prospective, 8 weeks, double blind study. Blinding: The&#xD;
      treatment administrator and the study personnel and patients will be masked to the treatment&#xD;
      being administrated.&#xD;
&#xD;
      Concurrent Control: The study group will receive active rTMS treatment and the control group&#xD;
      will receive an inactive, sham treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SANS</measure>
    <time_frame>1.5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFAS</measure>
    <time_frame>1.5 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>deep TMS treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>inactive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>H1 deep TMS coil</intervention_name>
    <description>20 daily deep rTMS treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>inactive treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients between the ages of 18-65 (male and female), Diagnosed in the past as&#xD;
             suffering from schizophrenia. The diagnosis will be reaffirmed according to ICD&#xD;
             criteria.&#xD;
&#xD;
          2. Right hand dominant.&#xD;
&#xD;
          3. Scores in PANSS negative questionnaire above 21.&#xD;
&#xD;
          4. Gave informed consent for participation in the study.&#xD;
&#xD;
          5. Negative answers on safety screening questionnaire for transcranial magnetic&#xD;
             stimulation&#xD;
&#xD;
          6. stable on the same antipsychotic medication for at least two months prior to entering&#xD;
             the study.&#xD;
&#xD;
          7. Negative answers to all questions in the TMS safety questionnaire (attached ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as suffering from another axis 1 disorder .&#xD;
&#xD;
          2. Scores in PANSS positive questionnaire above 24.&#xD;
&#xD;
          3. History of epilepsy, seizure, or hot spasm.&#xD;
&#xD;
          4. History of epilepsy within first-degree relatives.&#xD;
&#xD;
          5. History of head injuries.&#xD;
&#xD;
          6. History of metal in the head (outside the mouth space).&#xD;
&#xD;
          7. History of surgery including metal implant or history of metal particles in the eye,&#xD;
             pacemaker, or any other medical pump.&#xD;
&#xD;
          8. History of migraines.&#xD;
&#xD;
          9. History of hearing loss (not due to aging) or cochlear implants.&#xD;
&#xD;
         10. History of drug or alcohol abuse during the last year.&#xD;
&#xD;
         11. Women - Pregnancy or not using a reliable method of birth control.&#xD;
&#xD;
         12. Inability to achieve satisfying level of communication with the subject.&#xD;
&#xD;
         13. suicide attempt in the year prior to treatment or suicide risk according to a suicide&#xD;
             questionnaire&#xD;
&#xD;
         14. Custodians.&#xD;
&#xD;
         15. Participation in another medical study during the experiment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yechiel levkovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvate mental health center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>liron rabani, Phd. student</last_name>
    <phone>972-97478644</phone>
    <email>lironrab@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shalvata Mental Helath Center</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilik Levkovitz, prof.</last_name>
      <phone>972-9-7478569</phone>
      <email>ylevk@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shalvata</name>
      <address>
        <city>Hod hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>May 25, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>TMS</keyword>
  <keyword>brain stimulation</keyword>
  <keyword>negative symptoms</keyword>
  <keyword>clinical improvement</keyword>
  <keyword>cognitive improvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

